Background Human immunodeficiency virus (HIV) infection is the strongest risk factor for
developing tuberculosis and has fuelled its resurgence, especially in sub-Saharan Africa. In …

Two-thirds of the world's HIV-infected people live in sub-Saharan Africa, and more than 1.5
million of them die annually. As access to antiretroviral treatment has expanded within the …

Background Tuberculosis is the leading killer of patients with human immunodeficiency virus
(HIV) infection. Preventive therapy is effective, but current regimens are limited by poor …

[212] p.: graphs, maps, tablesIn embracing the targets in the 2011 Political Declaration,
countries committed to monitor and report on progress and challenges encountered in their …

This is the eighteenth global report on tuberculosis (TB) published by WHO in a series that
started in 1997. It provides a comprehensive and up-to-date assessment of the TB epidemic …

Background Antiretroviral therapy reduces the risk of tuberculosis, but tuberculosis is more
common in people with HIV than in people without HIV. We aimed to assess the effect of …

The billions of people with latent tuberculosis infection serve as the seedbeds for future
cases of active tuberculosis. Virtually all episodes of tuberculosis disease are preceded by a …

Background In accordance with WHO guidelines, people with HIV infection in Botswana
receive daily isoniazid preventive therapy against tuberculosis without obtaining a tuberculin …

The human immunodeficiency virus (HIV) pandemic presents a significant challenge to
global tuberculosis (TB) control. TB is a leading preventable cause of death among people …

Background Although antiretroviral therapy (ART) is known to be associated with time-
dependent reductions in tuberculosis (TB) incidence, the long-term impact of ART on …